CLDN18 and gastric cancer: Considering the relatively low PD-L1 expression and moderate CLDN18 positivity regardless of PD-L1 status, CLDN18 is a promising therapeutic target for patients with PD-positive gastric cancer who exhibit low PD-L1 expression.